

Ref. No.: LASA/SE/23-24/34
Tuesday, January 02, 2024

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

Sub. : **Update/ Revised Outcome of Board Meeting held on November 10, 2023**

Further to our outcome of Board Meeting held on November 10, 2023, we hereby enclosing Machine Readable Legible copy of Financial Result and Updated Limited Review Report for the Quarter and the half year ended September 30, 2023

Further, apart from the above mentioned details there is no other/material change made by the company in financials for the Quarter and the half year ended September 30, 2023.

Request you to take the same on your records.

FOR LASA SUPERGENERICS LIMITED

MITTI JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO.33681



Statement of Unaudited Financial Results for Quarter & Six Months ended 30th Sep, 2023

(Rs in Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
1. INCOME						
a. Revenue from Operations	2,430.26	3,055.60	3,366.12	5,485.86	6,254.00	12,956.78
b. Other Income	8.40	0.39	0.40	8.78	1.27	180.46
Total Income	2,438.66	3,055.98	3,366.53	5,494.64	6,255.26	13,137.24
2. Expenses						
a. Cost of Materials consumed	1,965.38	2,220.46	2,069.49	4,185.84	5,714.38	11,012.14
b. Cost of Traded Goods	-	-	-	-	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress	(314.44)	(189.95)	520.93	(504.39)	(192.23)	(400.71)
d. Employee benefits expenses	158.59	169.27	306.52	327.86	625.00	736.81
e. Finance costs (Bank Charges)	55.76	37.32	84.03	93.07	84.90	416.05
f. Depreciation & amortizations expenses	268.15	265.03	309.49	533.18	616.08	1,341.90
g. Other Expenses	516.40	450.78	503.23	967.18	953.66	2,267.90
Total Expenses (a to g)	2,649.83	2,952.91	3,793.68	5,602.74	7,801.79	15,374.09
Exceptional Items	-	-	246.80	-	246.80	1,989.66
3. Profit / (Loss) before tax (1-2)	(211.17)	103.06	(673.95)	(108.10)	(1,793.32)	(4,226.51)
4. Tax expense						
Current Tax	-	-	-	-	-	(368.77)
Deferred Tax	(208.89)	598.03	(17.60)	389.14	71.41	-
Short / Excess income tax provision for earlier years	-	-	4.33	-	4.33	4.33
5. Net Profit / (Loss) after tax (3-4)	(2.28)	(494.97)	(660.67)	(497.23)	(1,869.06)	(3,862.07)
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	-	3.91
7. Total Comprehensive Income for the year (after tax) (5+6)	(2.28)	(494.97)	(660.67)	(497.23)	(1,869.06)	(3,858.16)
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	5,010.12	5,010.13	4,067.27	5,010.12	4,067.27	5,952.98
9. Other Equity excluding Revaluation reserve as per Balance Sheet						
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	(0.00)	(0.99)	(1.62)	(0.99)	(4.60)	(6.49)
(b) Diluted	(0.00)	(0.99)	(1.62)	(0.99)	(4.60)	(6.49)

Notes :

1) "These interim condensed financial statements are prepared in accordance with Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting, under the historical cost convention on accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act, 2013 ("the Act") (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). Accordingly, these interim condensed financial statements do not include all the information required for a complete set of financial statements. These interim condensed financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report for the year ended March 31, 2023. The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter."

2) The Above Financial Results were reviewed by the audit committee of the board on 10th November 2023 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

3) The Company has paid advances Rs 470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd against which material was supposed to be supplied by OSCL, in the meantime OSCL admitted into CIRP, Company have filed claim with Resolution Professional status of which is still under inspection. The said advance is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers

4) Finance Cost for QE Sep'23, includes Rs 55,49,129/- provision for Interest on alleged ECB Loan (Which is Disputed) as per IND AS

5) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

6) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.



For Lasasupergenerics Ltd

Omkar Herlekar
Chairman & Managing Director
(DIN No. 01581154)

Place Mumbai

Date 10th November 2023

Factory & Regd. Office: E-4, C-11, M.I.D.C. LOTE PARSHURAM INDUSTRIAL AREA, TAL- KHED, DIST- RATNAGIRI 415722.

CIN: L24235MH2015PLC274202 Email : info@lasalabs.com Website : www.lasalabs.com

LASA SUPERGENERICS LIMITED
CIN: L24233MH2016PLC274202
Condensed Balance Sheet as at Sep 30, 2023

Particulars	Note No.	As at 30.09.2023	As at 30.09.2022
ASSETS			
Non-current assets			
Property, Plant and Equipment	3	8,685.22	11,190.77
Capital Work in Progress	3	464.47	582.44
Intangible assets	3	2,838.26	407.15
<u>Financial Assets</u>			
Non Current Investments	4	-	-
Deposits	5	60.98	1,492.68
		12,048.93	13,673.04
Current assets			
Inventories	6	1,997.58	1,205.80
<u>Financial Assets</u>			
Trade receivables	7	274.67	304.97
Cash and cash equivalents	8	96.77	303.71
Bank balances other than cash & cash equivalents	9	80.45	20.67
Loans	10	5.00	5.00
Other Financial Assets	11	7.55	-
Other current assets	12	2,083.87	2,552.26
		4,545.90	4,392.40
		16,594.82	18,065.45
EQUITY AND LIABILITIES			
EQUITY			
Equity Share capital	13	5,010.12	4,067.27
Other Equity	14	6,321.78	8,927.08
		11,331.90	12,994.35
LIABILITIES			
Non-current liabilities			
<u>Financial Liabilities</u>			
Non Current Borrowings		-	-
Provisions	15	64.52	59.43
Deferred Tax Liabilities	16	612.14	709.14
		676.66	768.57
<u>Current liabilities</u>			
<u>Financial Liabilities</u>			
Current Borrowings	17	105.50	-
Trade payables:	18		
Total outstanding dues of micro enterprises and small enterprises		120.35	208.06
Total outstanding dues of creditors other than micro enterprises and small enterprises		904.85	897.72
Other financial liabilities	19	2,199.26	2,159.39
Other current liabilities	20	144.58	142.29
Provisions	21	1,111.72	895.07
Current tax liabilities (net)		-	-
		4,586.26	4,302.53
		16,594.82	18,065.45

For Gupta Rustagi & Co.
Chartered Accountants
Firm Registration No.: 128701W

SD/-
CA Niraj Gupta
(Partner)
M.No.: 100808

Place : Mumbai
Date : 10th November 2023



For Lasa Supergenerics Limited


Omkar Herlekar
(Chairman & Managing Director)
DIN:01587154

LASA SUPERGENERICS LIMITED
CIN: L24233MH2016PLC274202
Statement of Condensed Cash flows for the period ended September 30, 2023

(Rs. in Lakhs)

Particulars	Half year ended 30 Sept 2023	Half year ended 30 Sept 2022	Year ended 31 March 2023
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net (loss) / profit before tax	(108.10)	(1,546.53)	(2,236.85)
Adjustments for			
Depreciation and Amortisation Expense	533.18	616.08	1,341.90
Finance Costs	93.07	84.90	416.06
Interest income	1.33	0.46	(180.46)
Remeasurement of employee defined benefit obligation	-	-	5.05
Exceptional Items	-	(246.80)	(1,989.66)
Profit on Sale of Investments	(7.43)	-	-
Operating profit before working capital changes	512.06	(1,091.88)	(2,643.98)
Working capital adjustments :-			
(Increase) / Decrease in Trade and Other Receivables	(26.88)	1,544.20	1,607.98
(Increase) / Decrease in Inventories	(607.28)	(56.03)	(240.53)
(Increase) / Decrease in Loans	-	(1,431.36)	(1.18)
(Increase) / Decrease in Other Current Assets	(43.92)	(82.67)	(142.29)
Increase / (Decrease) in Trade and Other Payables	82.47	(476.64)	(748.29)
Increase / (Decrease) in Provisions	101.40	299.03	410.27
Increase / (Decrease) in Other Financial Liabilities	22.27	142.30	159.90
Increase / (Decrease) in Other Current Liabilities	5.77	(22.43)	(127.58)
Cash generated from / (used in) operations	45.88	(1,175.48)	(1,725.71)
Direct taxes paid (Net of Refunds)	-	(4.33)	(4.33)
Net cash (used in) / from generated from operating activities	45.88	(1,179.81)	(1,730.04)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment and intangible assets (including capital work-in-progress and capital advances)	(160.86)	(129.63)	483.29
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	78.62	594.43	455.73
Net proceeds from Non Current Investments	31.16	-	-
Profit on Sale of Non Current Investments	7.43	-	-
Increase / (Decrease) in Deposits	3.46	-	-
Interest received	(1.33)	(0.46)	180.47
Net cash (used in) / generated from investing activities	(41.52)	464.34	1,119.49
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Share Capital (Considered as deemed inflow)	-	-	(416.06)
Proceeds from Capital Reserve	-	-	(416.06)
Interest paid	(93.07)	(84.90)	-
Proceeds from long-term borrowings (net)	-	-	(1,026.61)
Proceeds from short-term borrowings (net)	105.50	-	1,106.56
Redemption of investment	-	-	79.95
Net cash (used in) / from financing activities	12.43	(84.90)	-
Net decrease in cash and cash equivalents (A+B+C)	16.79	(800.38)	74.62
Cash and cash equivalents at the beginning of the year	79.95	1,104.08	5.33
Cash and cash equivalents at the end of the year	96.74	303.71	79.95
Components of cash and cash equivalents considered only for the purpose of cash flow statement			
In bank current accounts in Indian rupees	76.74	276.63	74.62
Cash on hand	20.01	27.07	5.33
	96.74	303.71	79.95

For Gupta Rustagi & Co.
Chartered Accountants
Firm Registration No.: 128701W

SD/-
CA Niraj Gupta
(Partner)
M.No.: 100808

Place : Mumbai
Date : 10th November 2023



For Lasa Supergenerics Limited

(Signature)
Omkar Herlekar
(Chairman & Managing Director)
DIN:01587154



Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of

Lasa Supergenerics Ltd

1. We have reviewed the accompanying statement of unaudited standalone financial results (The "Statement") of **Lasa Supergenerics Ltd** ('the Company') for the quarter ended September 30, 2023 and year to date from April 01, 2023 to September 30, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")
2. The statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of Material misstatement. A review is limited primarily to inquires of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. As mentioned in Note 3 of the Statement wherein the Company has mentioned has paid advances Rs.470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on




behalf of Omkar Speciality Chemicals Ltd (OSCL) against which material was supposed to be supplied by OSCL, in the meantime OSCL was admitted into CIRP on 20.12.2022, Company have filed claim with Resolution Professional status of which is still under inspection. The said advance is forming part of Other Current Assets- Advance paid to Suppliers. As mentioned in Note 3 of the accompanying statement of unaudited standalone financial results the Company has continued to carry this advance at book value. The impact of the same on the standalone financial statement of the Company is unascertainable at this stage.

5. Emphasis of Matter

The company does not have insurance cover for any of its assets. We are informed that company had disputed the insurance settlement amount offered by the insurance company against the claim filed by the company (flood insurance claim pertaining to 2019-20). The company should take immediate steps to resolve the issue and obtain necessary insurance cover to avoid any contingencies for which no provision has been made.

6. Based on our review conducted as above, *except for the possible effects of our observations in paragraph 4 above*, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Gupta Rustagi & Co.**
Chartered Accountants
ICAI FRN : 128701W



Niraj Gupta
Partner

M.N.no. 100808

Place: Mumbai

Date: 10.11.2023

UDIN: 23100808BGVNXI7156

